<DOC>
	<DOC>NCT01327547</DOC>
	<brief_summary>To describe liver enzyme elevations in patients who are coinfected with HIV and either Hepatitis C (HCV) and/or Hepatitis B (HBV) receiving maraviroc or placebo in combination with their current suppressive anti-HIV drug therapy.</brief_summary>
	<brief_title>A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>HIV coinfected with HCV and/or HBV. Undetectable HIV1 RNA for at least 3 months prior to the screening visit Treatment with current antiretroviral therapy (36 drugs excluding lowdose ritonavir) for at least 5 months. Currently receiving maraviroc. Active opportunistic infections. ALT and/or AST &gt;5x upper limit of normal. Direct bilirubin &gt;1.5x upper limit of normal. Severe or decompensated liver disease. Liver disease unrelated to viral hepatitis infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>HIV coinfection</keyword>
	<keyword>maraviroc</keyword>
	<keyword>CCR5 blocker</keyword>
	<keyword>entry inhibitor</keyword>
	<keyword>liver disease</keyword>
	<keyword>viral hepatitis</keyword>
</DOC>